康希诺生物股份公司关于ACYW135群脑膜炎球菌多糖结合疫苗 （CRM197载体）获得补充申请批准通知书的公告

Group 1 - The company received approval from the National Medical Products Administration to expand the age range for its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) from "3 months to 3 years (47 months) children" to "3 months to 6 years (83 months) children" [1] - The product, branded as "Mankai Xin," is the first quadrivalent meningococcal conjugate vaccine approved in China, which was launched in December 2021, addressing the gap in high-end vaccines in the country and providing a better solution for preventing meningococcal disease in children under 6 years old [2] - The expansion of the age range for Mankai Xin is expected to positively impact the company's performance by facilitating further promotion and use of the vaccine, with the company committed to advancing production, batch release, and market sales [2]